{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T22:57:40Z","timestamp":1792364260458,"version":"4.4.0"},"reference-count":79,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epigenomes"],"abstract":"<jats:p>Neurocutaneous syndromes, known as phakomatoses, encompass a diverse group of congenital conditions affecting the nervous system and skin, with neurofibromatosis type 1 (NF1) and neurofibromatosis type 2 (NF2) among the most clinically significant. Both disorders are inherited in an autosomal dominant manner. NF1 presents with caf\u00e9-au-lait macules; cutaneous, subcutaneous, and plexiform neurofibromas; skeletal abnormalities; learning disabilities; and optic pathway gliomas, while NF2 is characterised by bilateral vestibular schwannomas, multiple meningiomas, ependymomas, and peripheral nerve schwannomas. Although germline mutations in the NF1 and NF2 tumour suppressor genes are well established, they do not fully explain the broad clinical variability observed, even among individuals carrying identical mutations. As increasingly recognised in other genetic diseases, epigenetic mechanisms, including DNA methylation, histone modifications, chromatin remodelling, and non-coding RNA (ncRNA) regulation, play a critical role in modulating gene expression and influencing disease severity. Despite important findings, the research remains fragmented, and a unified model is lacking. This review organises the current knowledge, emphasising how epigenetic alterations impact disease behaviour and outlining their potential as prognostic biomarkers and therapeutic targets. A deeper understanding of these mechanisms could lead to improved personalised management and the development of targeted epigenetic therapies for individuals with NF1 and NF2.<\/jats:p>","DOI":"10.3390\/epigenomes9030030","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T15:16:37Z","timestamp":1755184597000},"page":"30","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Epigenetic Mechanisms in Neurofibromatosis Types 1 and 2"],"prefix":"10.3390","volume":"9","author":[{"given":"Christina","family":"Stylianides","sequence":"first","affiliation":[{"name":"Department of Histology-Embryology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavriel","family":"Hadjigavriel","sequence":"additional","affiliation":[{"name":"Department of Histology-Embryology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8607-6695","authenticated-orcid":false,"given":"Paschalis","family":"Theotokis","sequence":"additional","affiliation":[{"name":"Department of Histology-Embryology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstratios","family":"Vakirlis","sequence":"additional","affiliation":[{"name":"First Department of Dermatology and Venereology, School of Medicine, Aristotle University of Thessaloniki, 54643 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7929-9110","authenticated-orcid":false,"given":"Soultana","family":"Meditskou","sequence":"additional","affiliation":[{"name":"Department of Histology-Embryology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7075-878X","authenticated-orcid":false,"given":"Maria Eleni","family":"Manthou","sequence":"additional","affiliation":[{"name":"Department of Histology-Embryology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9134-1083","authenticated-orcid":false,"given":"Iasonas","family":"Dermitzakis","sequence":"additional","affiliation":[{"name":"Department of Histology-Embryology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pediatrneurol.2018.08.006","article-title":"Genetic Evaluation of Common Neurocutaneous Syndromes","volume":"89","year":"2018","journal-title":"Pediatr. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/B978-0-444-53485-9.00027-1","article-title":"Neurocutaneous Syndromes","volume":"135","author":"Klar","year":"2016","journal-title":"Handb. Clin. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Hadjigavriel, G., Stylianides, C., Axarloglou, E., Manthou, M.E., Vakirlis, E., Theotokis, P., Meditskou, S., and Dermitzakis, I. (2025). Epigenetic Insights into Tuberous Sclerosis Complex, Von Hippel\u2013Lindau Syndrome, and Ataxia\u2013Telangiectasia. Epigenomes, 9.","DOI":"10.3390\/epigenomes9020020"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/oxfordjournals.aje.a010118","article-title":"NF1 Gene and Neurofibromatosis 1","volume":"151","author":"Rasmussen","year":"2000","journal-title":"Am. J. Epidemiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1007\/s00381-020-04758-5","article-title":"Introduction to Phacomatoses (Neurocutaneous Disorders) in Childhood","volume":"36","author":"Ruggieri","year":"2020","journal-title":"Childs Nerv. Syst. ChNS Off. J. Int. Soc. Pediatr. Neurosurg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1212\/WNL.56.11.1433","article-title":"The Clinical and Diagnostic Implications of Mosaicism in the Neurofibromatoses","volume":"56","author":"Ruggieri","year":"2001","journal-title":"Neurology"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Kioutchoukova, I., Foster, D., Thakkar, R., Ciesla, C., Cabassa, J.S., Strouse, J., Kurz, H., and Lucke-Wold, B. (2024). Neurocutaneous Diseases: Diagnosis, Management, and Treatment. J. Clin. Med., 13.","DOI":"10.20944\/preprints202401.1301.v1"},{"key":"ref_8","first-page":"642","article-title":"Phacomatosis and genetically determined tumors: The transition from childhood to adulthood","volume":"54","author":"Vernet","year":"2008","journal-title":"Neurochirurgie"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.otorri.2009.12.005","article-title":"Neurofibromatosis type 2","volume":"61","author":"Prades","year":"2010","journal-title":"Acta Otorrinolaringol. Esp."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00401-019-02029-5","article-title":"An Update on the CNS Manifestations of Neurofibromatosis Type 2","volume":"139","author":"Coy","year":"2020","journal-title":"Acta Neuropathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101172","DOI":"10.1016\/j.spen.2024.101172","article-title":"Neurofibromatosis Type 1\u2014An Update","volume":"52","author":"Moodley","year":"2024","journal-title":"Semin. Pediatr. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/B978-0-444-62702-5.00004-4","article-title":"Chapter 4\u2014Neurofibromatosis Type 1","volume":"Volume 132","author":"Islam","year":"2015","journal-title":"Handbook of Clinical Neurology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/gcc.10282","article-title":"NF2: The Wizardry of Merlin","volume":"38","author":"Xiao","year":"2003","journal-title":"Genes. Chromosomes Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/GIM.0b013e3181bf15e3","article-title":"Clinical and Genetic Aspects of Neurofibromatosis 1","volume":"12","author":"Jett","year":"2010","journal-title":"Genet. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/hmg\/ddp212","article-title":"Unravelling the Genetic Basis of Variable Clinical Expression in Neurofibromatosis 1","volume":"18","author":"Sabbagh","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Teranishi, Y., Miyawaki, S., Nakatomi, H., Ohara, K., Hongo, H., Dofuku, S., Okano, A., Takayanagi, S., Ota, T., and Yoshimura, J. (2022). Early Prediction of Functional Prognosis in Neurofibromatosis Type 2 Patients Based on Genotype\u2013Phenotype Correlation with Targeted Deep Sequencing. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-13580-9"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Peduto, C., Zanobio, M., Nigro, V., Perrotta, S., Piluso, G., and Santoro, C. (2023). Neurofibromatosis Type 1: Pediatric Aspects and Review of Genotype\u2013Phenotype Correlations. Cancers, 15.","DOI":"10.3390\/cancers15041217"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s11912-023-01451-z","article-title":"Management of Central and Peripheral Nervous System Tumors in Patients with Neurofibromatosis","volume":"25","author":"Brown","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.2147\/JMDH.S362791","article-title":"Neurofibromatosis Type 1: Optimizing Management with a Multidisciplinary Approach","volume":"17","author":"Lalvani","year":"2024","journal-title":"J. Multidiscip. Healthc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.3390\/cimb45050272","article-title":"CNS Border-Associated Macrophages: Ontogeny and Potential Implication in Disease","volume":"45","author":"Dermitzakis","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.3390\/cimb44070222","article-title":"Developmental Cues and Molecular Drivers in Myelinogenesis: Revisiting Early Life to Re-Evaluate the Integrity of CNS Myelin","volume":"44","author":"Dermitzakis","year":"2022","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.3390\/cimb45030171","article-title":"Origin and Emergence of Microglia in the CNS-An Interesting (Hi)Story of an Eccentric Cell","volume":"45","author":"Dermitzakis","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"8118","DOI":"10.3390\/cimb46080481","article-title":"Ontogeny of Skin Stem Cells and Molecular Underpinnings","volume":"46","author":"Dermitzakis","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"8239","DOI":"10.3390\/cimb46080487","article-title":"Skin Development and Disease: A Molecular Perspective","volume":"46","author":"Dermitzakis","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Dermitzakis, I., Kyriakoudi, S.A., Chatzianagnosti, S., Chatzi, D., Vakirlis, E., Meditskou, S., Manthou, M.E., and Theotokis, P. (2025). Epigenetics in Skin Homeostasis and Ageing. Epigenomes, 9.","DOI":"10.3390\/epigenomes9010003"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00401-016-1540-6","article-title":"Methylation-Based Classification of Benign and Malignant Peripheral Nerve Sheath Tumors","volume":"131","author":"Koelsche","year":"2016","journal-title":"Acta Neuropathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41419-020-02909-9","article-title":"The Different Role of YKL-40 in Glioblastoma Is a Function of MGMT Promoter Methylation Status","volume":"11","author":"Chen","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature10833","article-title":"Driver Mutations in Histone H3.3 and Chromatin Remodelling Genes in Paediatric Glioblastoma","volume":"482","author":"Schwartzentruber","year":"2012","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Gorini, F., Miceli, M., de Antonellis, P., Amente, S., Zollo, M., and Ferrucci, V. (2023). Epigenetics and Immune Cells in Medulloblastoma. Front. Genet., 14.","DOI":"10.3389\/fgene.2023.1135404"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00401-022-02513-5","article-title":"Expanded Analysis of High-Grade Astrocytoma with Piloid Features Identifies an Epigenetically and Clinically Distinct Subtype Associated with Neurofibromatosis Type 1","volume":"145","author":"Cimino","year":"2023","journal-title":"Acta Neuropathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/neuonc\/nou140","article-title":"Methylated RASSF1A in Malignant Peripheral Nerve Sheath Tumors Identifies Neurofibromatosis Type 1 Patients with Inferior Prognosis","volume":"17","author":"Danielsen","year":"2015","journal-title":"Neuro-Oncology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","article-title":"Neurofibromatosis Type 1","volume":"3","author":"Gutmann","year":"2017","journal-title":"Nat. Rev. Dis. Primer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.18632\/oncotarget.2194","article-title":"The NF1 Gene Revisited\u2014From Bench to Bedside","volume":"5","author":"Yap","year":"2014","journal-title":"Oncotarget"},{"key":"ref_34","first-page":"465","article-title":"An Update on Neurofibromatosis Type 1: Not Just Caf\u00e9-Au-Lait Spots and Freckling. Part II. Other Skin Manifestations Characteristic of NF1. NF1 and Cancer","volume":"107","year":"2016","journal-title":"Actas Dermosifiliogr."},{"key":"ref_35","first-page":"e371","article-title":"Cutaneous Manifestations in Neurofibromatosis Type 1","volume":"171","author":"Miraglia","year":"2020","journal-title":"Clin. Ter."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Cassina, M., Frizziero, L., Opocher, E., Parrozzani, R., Sorrentino, U., Viscardi, E., Miglionico, G., Midena, E., Clementi, M., and Trevisson, E. (2019). Optic Pathway Glioma in Type 1 Neurofibromatosis: Review of Its Pathogenesis, Diagnostic Assessment, and Treatment Recommendations. Cancers, 11.","DOI":"10.3390\/cancers11111790"},{"key":"ref_37","first-page":"161","article-title":"Skeletal Muscle and Motor Deficits in Neurofibromatosis Type 1","volume":"15","author":"Summers","year":"2015","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"ref_38","first-page":"70","article-title":"The Skeletal Muscle Phenotype of Children with Neurofibromatosis Type 1\u2014A Clinical Perspective","volume":"22","author":"Chinoy","year":"2022","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.nrl.2019.05.003","article-title":"Neurological Manifestations of Neurofibromatosis Type 1: Our Experience","volume":"37","year":"2022","journal-title":"Neurologia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4103\/ijri.IJRI_497_19","article-title":"Phakomatoses: A Pictorial Review","volume":"30","author":"Swarup","year":"2020","journal-title":"Indian J. Radiol. Imaging"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/neuros\/nyab021","article-title":"Diagnostic Pathology of Tumors of Peripheral Nerve","volume":"88","author":"Belakhoua","year":"2021","journal-title":"Neurosurgery"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.ajpath.2010.12.056","article-title":"The Pathoetiology of Neurofibromatosis 1","volume":"178","author":"Jouhilahti","year":"2011","journal-title":"Am. J. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/ejhg.2009.129","article-title":"Differential MSH2 Promoter Methylation in Blood Cells of Neurofibromatosis Type 1 (NF1) Patients","volume":"18","author":"Titze","year":"2010","journal-title":"Eur. J. Hum. Genet. EJHG"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13072-020-00380-6","article-title":"Distinctive Epigenomic Alterations in NF1-Deficient Cutaneous and Plexiform Neurofibromas Drive Differential MKK\/P38 Signaling","volume":"14","author":"Grit","year":"2021","journal-title":"Epigenet. Chromatin"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1375\/twin.13.6.582","article-title":"Monozygotic Twins with Neurofibromatosis Type 1 (NF1) Display Differences in Methylation of NF1 Gene Promoter Elements, 5\u2019 Untranslated Region, Exon and Intron 1","volume":"13","author":"Harder","year":"2010","journal-title":"Twin Res. Hum. Genet. Off. J. Int. Soc. Twin Stud."},{"key":"ref_46","first-page":"2820","article-title":"Methylation Analysis of the Neurofibromatosis Type 1 (NF1) Promoter in Peripheral Nerve Sheath Tumours","volume":"40","author":"Harder","year":"2004","journal-title":"Eur. J. Cancer Oxf. Engl. 1990"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/sj.ejhg.5200565","article-title":"Microsatellite Instability and Promoter Methylation as Possible Causes of NF1 Gene Inactivation in Neurofibromas","volume":"8","author":"Luijten","year":"2000","journal-title":"Eur. J. Hum. Genet. EJHG"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cancergencyto.2004.08.016","article-title":"Analysis of Somatic NF1 Promoter Methylation in Plexiform Neurofibromas and Schwann Cells","volume":"157","author":"Fishbein","year":"2005","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s004390000322","article-title":"Hypermethylation of the Neurofibromatosis Type 1 (NF1) Gene Promoter Is Not a Common Event in the Inactivation of the NF1 Gene in NF1-Specific Tumours","volume":"107","author":"Horan","year":"2000","journal-title":"Hum. Genet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/jnci\/djr416","article-title":"Role of Noncoding RNA ANRIL in Genesis of Plexiform Neurofibromas in Neurofibromatosis Type 1","volume":"103","author":"Pasmant","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Mu\u00dfotter, T., Kluwe, L., H\u00f6gel, J., Nguyen, R., Cooper, D.N., Mautner, V.-F., and Kehrer-Sawatzki, H. (2012). Non-Coding RNA ANRIL and the Number of Plexiform Neurofibromas in Patients with NF1 Microdeletions. BMC Med. Genet., 13.","DOI":"10.1186\/1471-2350-13-98"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/mc.23825","article-title":"Plasma DNA Methylation-Based Biomarkers for MPNST Detection in Patients with Neurofibromatosis Type 1","volume":"64","author":"Tomczak","year":"2025","journal-title":"Mol. Carcinog."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1158\/1078-0432.CCR-14-3049","article-title":"Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-Plexiform Neurofibroma","volume":"21","author":"Hirbe","year":"2015","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"dmm050581","DOI":"10.1242\/dmm.050581","article-title":"Telomere Length Is an Epigenetic Trait\u2014Implications for the Use of Telomerase-Deficient Organisms to Model Human Disease","volume":"17","author":"Henriques","year":"2024","journal-title":"Dis. Model. Mech."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Dogan, F., and Forsyth, N.R. (2021). Telomerase Regulation: A Role for Epigenetics. Cancers, 13.","DOI":"10.3390\/cancers13061213"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3892\/or.2014.3379","article-title":"TAGLN Expression Is Upregulated in NF1-Associated Malignant Peripheral Nerve Sheath Tumors by Hypomethylation in Its Promoter and Subpromoter Regions","volume":"32","author":"Park","year":"2014","journal-title":"Oncol. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/ng.3095","article-title":"PRC2 Is Recurrently Inactivated through EED or SUZ12 Loss in Malignant Peripheral Nerve Sheath Tumors","volume":"46","author":"Lee","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/modpathol.2016.45","article-title":"Loss of H3K27 Tri-Methylation Is a Diagnostic Marker for Malignant Peripheral Nerve Sheath Tumors and an Indicator for an Inferior Survival","volume":"29","author":"Cleven","year":"2016","journal-title":"Mod. Pathol. Off. J. United States Can. Acad. Pathol. Inc."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/modpathol.2015.134","article-title":"Loss of H3K27 Trimethylation Distinguishes Malignant Peripheral Nerve Sheath Tumors from Histologic Mimics","volume":"29","author":"Schaefer","year":"2016","journal-title":"Mod. Pathol. Off. J. United States Can. Acad. Pathol. Inc."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1158\/0008-5472.CAN-10-2799","article-title":"Autophagic Survival in Resistance to Histone Deacetylase Inhibitors: Novel Strategies to Treat Malignant Peripheral Nerve Sheath Tumors","volume":"71","author":"Lopez","year":"2011","journal-title":"Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nature13561","article-title":"PRC2 Loss Amplifies Ras-Driven Transcription and Confers Sensitivity to BRD4-Based Therapies","volume":"514","author":"Beert","year":"2014","journal-title":"Nature"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/path.2633","article-title":"Genome-Wide Transcriptome Analyses Reveal P53 Inactivation Mediated Loss of miR-34a Expression in Malignant Peripheral Nerve Sheath Tumours","volume":"220","author":"Subramanian","year":"2010","journal-title":"J. Pathol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1111\/j.1349-7006.2010.01616.x","article-title":"MicroRNA-10b Regulates Tumorigenesis in Neurofibromatosis Type 1","volume":"101","author":"Chai","year":"2010","journal-title":"Cancer Sci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/bjc.2012.518","article-title":"MicroRNA Profiling of Peripheral Nerve Sheath Tumours Identifies miR-29c as a Tumour Suppressor Gene Involved in Tumour Progression","volume":"108","author":"Presneau","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"109226","DOI":"10.1016\/j.heares.2025.109226","article-title":"NF2-Related Schwannomatosis: A View from within the Inner Ear","volume":"460","author":"Brown","year":"2025","journal-title":"Hear. Res."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Tamura, R. (2021). Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115850"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12935-023-02940-8","article-title":"The Genetic Landscape and Possible Therapeutics of Neurofibromatosis Type 2","volume":"23","author":"Ghalavand","year":"2023","journal-title":"Cancer Cell Int."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Lee, J.D., Kwon, T.J., Kim, U.-K., and Lee, W.-S. (2012). Genetic and Epigenetic Alterations of the NF2 Gene in Sporadic Vestibular Schwannomas. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0030418"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Bachir, S., Shah, S., Shapiro, S., Koehler, A., Mahammedi, A., Samy, R.N., Zuccarello, M., Schorry, E., and Sengupta, S. (2021). Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020690"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.spen.2015.10.008","article-title":"Diagnosis, Management, and New Therapeutic Options in Childhood Neurofibromatosis Type 2 and Related Forms","volume":"22","author":"Ruggieri","year":"2015","journal-title":"Semin. Pediatr. Neurol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/0883073816666736","article-title":"Neurofibromatosis Type 2","volume":"32","author":"Fisher","year":"2017","journal-title":"J. Child Neurol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11060-010-0386-3","article-title":"Epidemiology and Etiology of Meningioma","volume":"99","author":"Wiemels","year":"2010","journal-title":"J. Neurooncol."},{"key":"ref_73","unstructured":"Adam, M.P., Feldman, J., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., and Amemiya, A. (1993). NF2-Related Schwannomatosis. GeneReviews\u00ae, University of Washington."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2176\/jns-nmc.2024-0067","article-title":"Historical Development of Diagnostic Criteria for NF2-Related Schwannomatosis","volume":"64","author":"Tamura","year":"2024","journal-title":"Neurol. Med. Chir."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1750-1172-4-16","article-title":"Neurofibromatosis Type 2 (NF2): A Clinical and Molecular Review","volume":"4","author":"Evans","year":"2009","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_76","first-page":"5601","article-title":"CpG Island Methylation in Sporadic and Neurofibromatis Type 2-Associated Schwannomas","volume":"9","author":"Bello","year":"2003","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1365-2443.2001.00432.x","article-title":"Identification of the Cis-Acting Region in the NF2 Gene Promoter as a Potential Target for Mutation and Methylation-Dependent Silencing in Schwannoma","volume":"6","author":"Kino","year":"2001","journal-title":"Genes Cells Devoted Mol. Cell. Mech."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Torres-Martin, M., Lassaletta, L., de Campos, J.M., Isla, A., Gavilan, J., Pinto, G.R., Burbano, R.R., Latif, F., Melendez, B., and Castresana, J.S. (2013). Global Profiling in Vestibular Schwannomas Shows Critical Deregulation of microRNAs and Upregulation in Those Included in Chromosomal Region 14q32. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0065868"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/gcc.22232","article-title":"Genome-Wide Methylation Analysis in Vestibular Schwannomas Shows Putative Mechanisms of Gene Expression Modulation and Global Hypomethylation at the HOX Gene Cluster","volume":"54","author":"Lassaletta","year":"2015","journal-title":"Genes Chromosomes Cancer"}],"container-title":["Epigenomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4655\/9\/3\/30\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:27:44Z","timestamp":1760034464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4655\/9\/3\/30"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":79,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["epigenomes9030030"],"URL":"https:\/\/doi.org\/10.3390\/epigenomes9030030","relation":{},"ISSN":["2075-4655"],"issn-type":[{"value":"2075-4655","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]}}}